Lower Doses of Ilaris Can Maintain Clinical Remission in Systemic-onset JIA, Trial Shows
News
Treatment with Ilaris (canakinumab) at doses lower than the one recommended might be enough to maintain clinical remission in people with systemic juvenile idiopathic arthritis (sJIA), clinical data show. Yet, as ... Read more